期刊
CURRENT OPINION IN INFECTIOUS DISEASES
卷 26, 期 6, 页码 567-574出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QCO.0000000000000016
关键词
control; dengue; review; therapeutics
资金
- Wellcome Trust, UK
- National Institute for Health Research Biomedical Research Centre
- Funding Scheme
- Office of the Higher Education Commission
- Mahidol University under National Research Universities Initiative
- European Commission [282 378]
- MRC [G0801508, G0400720, G0600000] Funding Source: UKRI
- Medical Research Council [G0400720, G0801508] Funding Source: researchfish
Purpose of reviewDengue is a rapidly spreading vector-borne disease estimated to infect 400 million people worldwide. To date, there are no licensed treatments or vaccines. The last few years have seen significant developments in dengue control strategies. In this review, we will address four key areas: vaccines, vector control, antivirals and immunotherapeutics.Recent findingsThe first generation of dengue vaccines is able to induce good serological responses in test individuals. However, the recent Sanofi-Pasteur trial in Thailand found that a good serological response did not correlate with clinical protection. This trial did not demonstrate an increase in cases of severe disease following immunization, suggesting that concerns over vaccine-related immune enhancement may have been overcome. The bacterium Wolbachia appears to control dengue proliferation in Aedes mosquitoes, and field studies are underway. A large number of antivirals are in early-stage development and may prove useful in epidemics. Monoclonal antibodies have been postulated to have a clinical role. Whether their clinical application is feasible has yet to be seen.SummaryMarked improvements in our knowledge of dengue have been made over the recent years. Sadly, clinical application remains some years away.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据